Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 15, 2023

BUY
$8.22 - $10.76 $87,132 - $114,056
10,600 New
10,600 $87,000
Q2 2022

Aug 15, 2022

BUY
$6.46 - $10.02 $1.25 Million - $1.93 Million
193,024 New
193,024 $1.78 Million

Others Institutions Holding BLU

# of Institutions
1
Shares Held
128K
Call Options Held
0
Put Options Held
0

About BELLUS Health Inc.


  • Ticker BLU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,793,000
  • Description
  • BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...
More about BLU
Track This Portfolio

Track Western Standard LLC Portfolio

Follow Western Standard LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Western Standard LLC, based on Form 13F filings with the SEC.

News

Stay updated on Western Standard LLC with notifications on news.